Antivenom Market Outlook
Antivenom is also called as antivenin. Antivenom is a medication prepared from antibodies which are used to treat certain venomous bites. Poisonous bites result in certain clinical conditions such as muscle weakness, secretion of excessive saliva, breathing problems, along with other difficulties, in some instance that might lead to death as well. Antivenins are recommended only if there is significant toxicity or high risk of toxicity. Antivenom is made by collecting venom from the relevant venomous species of spider, snake, fish, injecting venom in little amounts to domestic animals and antibodies are separated from blood purification. These antibodies are used as antivenom.
Antivenom market is segmented based on product type, animal, and distribution channel
Based on product type, the market has been segmented into
Based on animal, the market is segmented into
Based on distribution channel, the market is segmented into
- Hospital Pharmacies
- Retail Pharmacies
Antivenom Market Geographically Segmentation
Geographically market is segmented into following regions viz. North America, Asia-Pacific, Latin America, Europe, and Middle East & Africa. North America contributes a major share in market due to the establishment of snake poison control centres, increase in antivenom products approval, rise in number of antivenom clinical trial conducting firms and presence of established health care facilities. Asia Pacific anti venom market is expected to have lucrative market growth owing to increase in number of snake bite cases as compared to developed regions.
Furthermore, development of antivenom products for several species of snakes, rising demand for antivenom products, and increase in a number of local antivenom manufacturers such as Bharath Serum, Vaccines Limited and Vins Bioproducts focusing on antivenom products in the Asia region. In the case of the Middle East and Africa region, South Africa expected to have significant growth opportunity due to the highest number of snake bites in the country. Many of the global players are expected to expand their business to African market during the forecast period.
Antivenom Market Growth Analysis
Increase in government initiatives to develop antivenoms and incidents of the venomous bites in undeveloped regions are fueling the growth of market over the forecast period. In addition, rise in deaths due to venomous bites and technological advancements in the development of antivenom creates significant opportunities for the antivenom manufacturers. However, complexity in regulatory procedures, insufficient funding in development of antivenom, and high cost of the product are hindering growth.
Growing demand of antivenom worldwide, especially in Africa and Asia-Pacific region owing to more number of venomous bite incidents. According to World Health Organization (WHO), about 5 Mn snake bites occur each year, resulting 2.5 Mn envenomings (poisoning because of snake bites), minimum 100,000 deaths and around three times as many amputations and other permanent disabilities. Withdrawal of antivenoms like Fav-Afrique by Pfizer further grew demand for the market. Market players are also actively involving in R&D to develop antivenoms and to enhance their market position. In addition, many market players and institutions are actively involved in the development of new antivenoms. For instance, Equine F (ab’) 2 in antivenin is being developed by Instituto Bioclon S.A (clinical trials phase 2) for treatment of poisoning by scorpion sting. Based on the aforementioned factors market is expected to grow with significant CAGR rate during the forecast period.
Antivenom Market Key Players are Vins Bioproducts Limited (India), Bharat Serum and Vaccines Limited (India), CSL Limited (Victoria), Rare Disease Therapeutics, Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), Instituto Bioclon, S.A. de C.V.(Mexico), Incepta Vaccine Ltd. (Bangladesh), BTG Plc (U.K), Merck & Co., Inc. (U.S), and Pfizer Inc. (U.S.), to name a few
- In June 2015, Incepta Pharmaceuticals Limited introduced first ever locally manufactured antivenom injection in the name of antivenom
- The report provides granular level information about the market size, regional market share and forecast from 2018-2024
- The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
- The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
- The report tracks recent innovations, key developments and startup’s details that are working in the industry
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario